Healthcare & Life Sciences Insights

Discover Latham’s latest insights into the commercial, regulatory, and legal developments shaping the global healthcare and life sciences landscape.

Latham’s cross-disciplinary team delivers insightful, practical guidance and sophisticated representation to a full spectrum of healthcare and life sciences companies across the globe, on every type of transaction or dispute a company may face.

Learn more about our capabilities

Pipetting a DNA (deoxyribonucleic acid) sample into a multiwell plate with DNA information in the background

In the Spotlight

Healthcare & Life Sciences Market Update

Shiny transparent capsule filled with colorful spheres

June 2, 2025 Newsletter

Healthcare & Life Sciences: Drug Pricing Digest — Number 47

Close-up of pipette releasing clear liquid droplet into a petri dish with DNA sequencing image in background.

May 16, 2025 Blog

100 Days In: FDA Updates and Trends to Watch

artificial intelligence machine learning big data concept

April 17, 2025 Blog

Preparing for the European Health Data Space — Opportunities and Challenges for Europe’s Digital Future

March 5, 2025 Blog

HHS Issues Policy Statement to Expand Use of Rulemaking Without Notice and Comment

Digitally rendered gel capsule filled with multicolor spheres.

August 11, 2025 Newsletter

Healthcare & Life Sciences: Drug Pricing Digest — Number 52

Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law.

Digitally rendered image electrocardiograph line.

July 30, 2025 Webcast

Healthcare Implications of the One Big Beautiful Bill: What You Need to Know

Members of Latham’s Healthcare & Life Sciences Practice discuss impacts of the OBBB’s healthcare policy provisions. MCLE credit offered.

July 28, 2025 Newsletter

Healthcare & Life Sciences: Drug Pricing Digest — Number 51

July 14, 2025 Newsletter

Healthcare & Life Sciences: Drug Pricing Digest — Number 50

July 8, 2025 Client Alert

Senators Introduce Legislation to Restrict Direct-to-Consumer Drug Advertising

June 24, 2025

Episode 99 — Drug Pricing: Takeaways From the Philadelphia Pricing and Contracting USA Conference

Join the Latham team and Allan Thoen from Sandoz to hear about the key themes and highlights from one of the year’s significant drug pricing conferences.

Abstract background of wires and glowing particles

June 26, 2025

Access Denied — Navigating the New DOJ Data Security Program With Confidence

Latham’s team of lawyers focusing on data security and national security examine DOJ’s DSP and its potential implications for companies. MCLE credit offered.

June 06, 2025

Episode 98 — Drug Pricing: Takeaways From the MDMA Annual Meeting

One of the country’s largest medical innovation and policy conferences recently concluded in Washington, D.C. Join the Latham team to discuss takeaways from the meeting, including regulatory changes and compliance hot topics.

May 02, 2025

Episode 97 — Drug Pricing: How the Drug Pricing EO Impacts FDA and Overlaps With Grassley-Led Legislation

On April 15, President Trump signed an executive order addressing prescription drug prices. The Latham team analyzes how the EO might impact FDA and dovetails with five bills recently (re-)introduced in the Senate.

March 12, 2025

Episode 95 — Drug Pricing: FDA in the Age of Executive Orders and DOGE

The Department of Government Efficiency, Trump executive orders, and a recent Office of Management and Budget memorandum are making drastic changes at FDA. The Latham team discusses the potential impacts on FDA approval and enforcement activities, including with respect to novel tobacco and nicotine products.

February 25, 2025

Episode 94 — Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook

One of the country’s largest healthcare conferences recently concluded in San Francisco. Join the Latham team to discuss takeaways from the conference, including AI innovation and increased dealmaking activity, and consider the policy outlook under the new Trump administration.

Drop of clear blue liquid from droper droping to test tube in laboratory with bright color blur background.

December 30, 2024

Episode 89 — The Growth Rocketship: How BridgeBio’s Hub and Spoke Portfolio Strategy Set the Market for the Future of Biotech — Then, Now, and What’s Next?

Latham speaks with BridgeBio’s CEO/founder and CFO about BBIO’s growth story — its past, present, and future.

December 17, 2024

Episode 88 — Drug Pricing: How Might the Trump Administration Transform FDA Enforcement Activities?

Explore recent FDA enforcement trends and the agency’s current focus, and consider potential priorities under the incoming Trump Administration.

November 26, 2024

Episode 87 — Drug Pricing: What’s in the New CMS Medicaid Final Rule?

CMS sought far-reaching changes to the Medicaid Drug Rebate Program in its 2023 proposed rule implementing the Medicaid Services Investment and Accountability Act. Find out which proposals CMS dropped from the final rule, and which changes became effective November 19, 2024.

October 21, 2024

Episode 86 — Drug Pricing: Takeaways From the Chicago Medicaid Drug Rebate Program Summit

One of the year’s major drug pricing conferences just concluded in Chicago. Join the Latham team to discuss takeaways from the conference, including highlights from remarks by government speakers.

Front View of US Supreme Court in Washington DC, including the inscription Equal Justine Under Law

September 19, 2024

The Demise of Chevron Deference and Its Impact on the Healthcare and Life Sciences Industries

Latham lawyers discuss the implications of the US Supreme Court decision in Loper Bright. MCLE credit offered.

September 19, 2024

Episode 85 — Drug Pricing: How the Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry

Recent Supreme Court decisions, such as those overruling Chevron deference, as well as ongoing manufacturer challenges to the Inflation Reduction Act and state 340B laws, will likely have a significant impact on the pharmaceutical industry.

August 19, 2024

Episode 83 — Drug Pricing: How Are Payers Responding to the IRA?

Explore how health insurance companies are adapting to the Inflation Reduction Act's new requirements, including the Part D redesign.

June 21, 2024

Episode 82 — Drug Pricing: Takeaways From the New Orleans Pricing and Contracting USA Conference

One of the year’s major drug pricing conferences just concluded in New Orleans. Join the Latham team to discuss takeaways from the conference, with topics including 340B developments, state legislative activity, and IRA implementation.

June 13, 2024

Episode 81 — Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other Data Collection Portals

The new ASP reporting website highlights the increasing significance of data collection portals — and yet the number of permitted users is very small. Join us as we learn from leading practitioners at Riparian how to navigate the complex web of compliance requirements.

Our Archive

Close-up of stethoscope on desk with doctor's hands out of focus in background typing on a laptop.

August 21, 2025 Our Work

Latham & Watkins Represents Modivcare in Comprehensive Restructuring Agreement

Restructuring & Special Situations team represents the technology-enabled healthcare services company in its pre-arranged Chapter 11 process to strengthen its future, reduce debt, and inject capital.

Medical professionals performing surgery in an operating room.

August 18, 2025 Our Work

Latham Advises on Kangji Medical Proposed Privatization

Hong Kong team represents Kangji Medical co-founders in the transaction.

August 14, 2025 Our Work

Latham & Watkins Advises on Heron Therapeutics Credit Restructuring and Senior Credit Facility of Up to US$150 Million

August 14, 2025 Our Work

Latham & Watkins Advises Healthpeak on US$500 Million Senior Unsecured Notes Offering

August 12, 2025 Our Work

Latham & Watkins Advises GreyLion Partners in Investment in Slipstream IT

Soft focus bokeh light effects over a rippled, blue water background in the pool.

August 22, 2025 Recognition

Litigator of the Week Runners-Up and Shout-Outs — Cendyn and ChemoCentryx (Amgen)

A Latham antitrust and appellate litigation team secured a landmark affirmance in an algorithmic pricing dispute. A separate litigation team secured a total summary judgment victory in a securities class action dispute.

Light Christmas Golden Luxury Glitter Background.

July 11, 2025 Recognition

Latham Ranks #1 M&A and Private Equity Law Firm Globally in H1 2025 League Tables

Firm’s M&A and Private Equity Practice earned top rankings across global, regional, and industry league tables, highlighting market leadership on the range of sophisticated transactions.

July 11, 2025 Recognition

Litigator of the Week Runners-Up and Shout-Outs — Recor Medical

An intellectual property team secured the dismissal of counterclaims in a patent litigation case for their client Recor against market rival Medtronic

Capital Markets European Union Life Sciences Regulatory FDA Regulatory Healthcare & Life Sciences Healthcare Regulatory Intellectual Property Litigation Life Sciences Licensing Litigation & Trial Mergers & Acquisitions Private Equity Public Company Representation Securities and M&A Litigation Technology

The Book of Jargon® Series

Book of Jargon Healthcare & Life Sciences

Download the App

Relator

The Book of Jargon® – Healthcare & Life Sciences

the private citizen or whistleblower who files suit under the False Claims Act on behalf of the government to assist in the prosecution of false or fraudulent conduct. After an investigatory period, the government then has the choice to either take over and prosecute the suit (typically called intervening) or to decline intervention in the case. Relators may receive a part of any recovery by the government, usually between 15-30%, plus attorney’s fees. If the government declines intervention, the relator can proceed alone as plaintiff on behalf of the government.

Word of the Day®

Licensed Patents

The Book of Jargon® – Healthcare & Life Sciences

the Patents and patent applications that are licensed to a Licensee by the Licensor pursuant to a License.

Word of the Day®

Declaratory Judgment

The Book of Jargon® – Healthcare & Life Sciences

a legal determination by a court resolving an issue affecting the rights of the parties to a dispute. Declaratory Judgments are common in Patent litigation because they allow alleged infringers to seek judicial determination of, for example, validity, non-infringement or enforceability of an Asserted Patent before the patent owner brings suit. A Declaratory Judgment action may allow the alleged infringer to determine the forum of the lawsuit.

Word of the Day®

Inter Partes Review (IPR)

The Book of Jargon® – Healthcare & Life Sciences

a PTAB proceeding for challenging the validity of any issued Patent. IPR may be requested on the basis of Novelty and Obviousness, and only Patents and printed publications may be used as prior art. 37 C.F.R. § 42.104(b).
The PTAB will not institute a petition for IPR if the Petitioner previously filed a Declaratory Judgement action challenging the Patent’s validity. But a Declaratory Judgement action filed as a counterclaim to an infringement suit does not bar instituting an IPR. 37 C.F.R. § 42.101.
IPR may be requested at any time for first-to-invent Patents. But for first-to-file Patents, IPR may only be requested nine months after the issuance or later (the period when a Petition for post- grant review could be filed). 37 C.F.R. § 42.102. And if Petitioner has been served with a patent infringement complaint, then the Petition must be filed in the PTAB within one year after service. 35 U.S.C. § 315(b).

Word of the Day®